## European Centre for Disease Prevention and Control

## Measles elimination: what to do if the present options are not used/implemented

Pier Luigi Lopalco, Head of Vaccine Preventable Diseases programme
Nicosia, 5 July 2012

## Eradication or Elimination?

WHO goals*:

- by end 2015 achieve regional measles and rubella elimination goals
- by end $\mathbf{2 0 2 0}$ achieve measles and rubella elimination in at least five regions
- by end 2015 establish a target date for the global eradication of measles
- by end 2020 establish a target date for the global eradication of rubella

[^0]
## Strategy components

1. Achieve and maintain high level immunisation
2. Monitor disease and programmatic efforts
3. Outbreak control
4. Communication to build public confidence
5. Research to improve vaccination, diagnostic tools and support cost-effective operations

## What's up in Europe?

## Reported measles cases in the EU/EEA 2005/2010



## Measles in Europe, 2011

Measles vaccine coverage (two doses, 2010)

| $\square$ |
| :--- |
|  |
|  | No coverages reported 2010

Number of cases


|  | Andorra |
| :--- | :--- |
|  | Liechtenstein |
|  | Malta |
|  | Monaco |
|  | San Marino |

Measles cases in the EU n. 30,567 (Jan-Dec 2011, ECDC) and vaccination coverage (2010, WHO)

## Measles: a severe disease

| Outcome | Number <br> of cases | $\%$ |
| :--- | :--- | :--- |
| Deaths | 8 | 0.03 |
| Cases with information on outcome status | 23.317 | 76.3 |
| No information provided/unknown | 7242 | 23.7 |
| Complications | 27 | 0.1 |
| Encephalitis | 1482 | 4.9 |
| Pneumonia | 149 | 0.5 |
| Diarrhoea | 234 | 0.8 |
| Otitis media | 1841 | 6.0 |
| Other complications | 3921 | 12.7 |
| No complications | 22913 | 75.0 |
| No information provided / unknown | 30567 |  |
| Total cases |  |  |

## Age-specific notification rate of Measles per 100.000 population, Europe, Jan-Dec 2011



## Vaccination status of reported cases (known for 83\% of cases)

- $82 \%(20,902)$ were unvaccinated
- $18 \%(4,586)$ vaccinated, but only $4 \%(920)$ vaccinated with two doses


## 45\%

rough estimate of vaccine coverage
in the population
where cases originated *

## Coverage for one dose of MMR in EU 2000-2010

|  | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Austria | 74.7 | 78.5 | 78.5 | 78.8 | 73.5 | 91 | 80 | 77 | 83 | 76 |  |
| Belgium | 82.2 | 82.2 | 82.2 | 82.2 | 82.2 | 88 | 91.9 | 91.9 |  | 94 | 94 |
| Bulgaria | 88.6 | 90.1 | 92.1 | 95.5 | 94.7 | 96.2 | 95.7 | 96 | 95.9 | 96.1 | 96.5 |
| Cyprus | 85 | 85 | 85 | 86 | 86.3 | 86.3 | 87 | 87 | 87 | 87 | 87 |
| Czech Republic | 98 | 98 | 99 | 99.1 | 96.9 |  |  | , |  |  | $\square$ |
| Denmark | 100 | 94 | 102.4 | 96 | 96 | 95 | 100 | 89 |  | 8.1 | 85 |
| Estonia | 93 | 94.7 | 95.2 | 95.2 | 95.5 | 95.9 | 96.1 | 95.5 | 9! | 75 | 95.1 |
| Finland | 96 | 96 | 95.8 | 97 | 97 | 97 | 97 | 98 | 97 | 98.5 |  |
| France | 84 | 85 | 85 | 86 | 85 |  |  | 9 9? | 87 | 90.1 | 90.1 |
| Germany | 91.7 | 91 | 91 | 92 | 92.5 | 93.3 | $\because 4$ | 94.5 | 95.4 | 95.9 | 96 |
| Greece | 88 | 88 | 88 | 88 | 88 |  |  |  | 98.9 | 98.9 |  |
| Hungary | 100 | 100 | 99.9 | 99.9 | 990 |  |  | < 7.9 | 99.9 | 99.8 | 99.9 |
| Iceland | 90 | 88 | 91 | 93 | 9 | 90 | 9. | 95 | 96 | 92 | 94 |
| Ireland | 79 | 73 | 72.5 | 78. | 81.1 | $24<$ | -6.2 | 87.02 | 89 | 90.4 | 90 |
| Italy | 74 | 76.5 | 7 | 33 | 84 | 5,7.2 | 87 | , |  |  |  |
| Latvia | 96.9 | 7\% 9 | 98.3 | 98 f | 98.) | 95 | 95.3 | 97 | 96.6 | 95.7 | 90.1 |
| Lithuania | $\bigcirc 7$ | 97.4 | 97.9 | 9. ${ }^{7}$ | 97.7 | 97.2 | 96.6 | 96.9 | 97 | 96 | 96.1 |
| Luxembourg | 91 | 91 | 9 C 4 | 95.4 | 95.4 | 95.4 |  | 96.2 | 96.2 | 96.2 | 96.2 |
| Malta | 74 | 65 | 05 | 90 | 87.4 | 86.01 | 94 | 79 | 78 | 82 | 72.55 |
| Netherlands | 95 | 95 | 96 | 95.7 | 96.27 | 96.3 |  | 95.9 | 96.2 | 96.2 | 95.9 |
| Norway | 92 | 93 | 88 | 84 | 88 | 90 | 91 | 92 | 93 | 92 | 93 |
| Poland | 97 | 97.2 | 97.6 | 97.5 | 97.4 | 98.2 | 98.2 | 98.3 |  | 98.3 | 98.2 |
| Portugal | 87 | 85.8 | 91.9 | 96.3 | 94.8 | 92.6 | 96.69 | 95 | 96.6 | 95 | 96 |
| Romania | 98 | 97.8 | 98.2 | 97.2 | 97.1 | 96.7 |  | 97.1 |  |  | 95 |
| Slovakia | 98 | 98.6 | 98.6 | 98.6 | 98 | 98 | 98.4 | 98.8 | 99 | 99 | 98.5 |
| Slovenia | 95.2 | 94 | 93.5 | 86.7 | 94 |  | 96.1 | 95.56 | 96 | 95 | 95 |
| Spain | 94 | 96 | 96.6 | 97.15 | 97.3 | 96.8 | 96.9 | 97.1 | 97.8 | 97.5 | 95.1 |
| Sweden | 94.2 | 88.5 | 95 | 95 | 94.5 | 95.4 | 95.4 | 96.2 | 96.2 | 96.7 | 96.5 |
| UK | 99 | 98.76 | 83 | 80 | 81 | 82.1 | 84.9 | 86.2 | 85.5 | 86 | 93 |

Source: WHO CISID

## Why measles still spread in Europe?

- A large population of susceptible individuals is still present in Europe.
- It is differently distributed:
- by country
- by age groups
- by social status

Solutions?

## Achieving high level immunisation

95\% active offer, specific tools
$90 \%$ structured vaccination programme
$80 \%$ vaccine recommendation

## Vaccination active offer a stepwise approach

## Safe and effective vaccine

## Active offer of MMR



# A strategy to immunize the susceptible age groups in Japan 

$$
(n=5,992)
$$



Source: Dr. Taya and Sato (IDSC/NIID)

## Anti-vaccine activists



XIX century


## Anti-vaccine activists

## some examples

homeopathy, naturopathy, alternative medicines

religious/philosophical beliefs
followers of conspiracy theories

## Underserved groups



Photo via http://www.flickrcom/photos/87563734@N00/, Henri Weisen

## The Vaccination Paradox



## Differences between MMR 1 and MMR2 vaccination coverage in 6 EU countries



## Complacency, the main issue



They just don't pay attention! used/implemented?

Active offer of two doses MMR to the target population

## Building trust in order to achieve and maintain high levels of vaccination coverage

## Thank you!

## pierluigi.|opalco@ecdc.europa.eu


[^0]:    * Global measles and rubella strategic plan 2012-2020

